Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • VistaGen Therapeutics, Inc. (VSTA) Continues To Move Forward With Revolutionary Drug Testing Technology 0 comments
    May 15, 2013 5:17 PM | about stocks: VSTA

    VistaGen is a biotech company focused on using stem cell technology to generate new, safer variants (drug rescue variants) of once-promising small molecule drug candidates that were developed but ultimately discontinued by large pharmaceutical companies due to heart or liver toxicity issues. VistaGen aims to use their proprietary stem cell technology as a previously unavailable cost effective way to re-examine and ultimately "rescue" such lost drugs, thereby recovering the value from what is usually a substantial prior investment in research and development.

    The company recognizes the drug discovery and development crisis facing the U.S. pharmaceutical industry, where increasingly big investments are required for new drug development but not enough new drugs are being finally approved. Using its technology to derive mature human heart and liver cells from pluripotent stem cells, VistaGen continues to develop unique bioassay systems for assessing potential toxicity issues right in the laboratory, providing a way for researchers to successfully modify drug candidates using an economical tweak and test approach.

    It's a development that combines human pluripotent stem cell technology with modern medicinal chemistry to create an important new tool for drug research and development. With human heart cells and liver cells derived from pluripotent stem cells, VistaGen believes that their principal products, CardioSafe 3D™ and LiverSafe 3D™, will allow them to assess the heart toxicity, liver toxicity, and metabolism profile of new drug candidates with greater speed and precision than animal testing and traditional cellular assays currently used in the drug development process.

    Although this represents an important new capability that could save the pharmaceutical industry billions of dollars in development costs which might otherwise be lost, VistaGen sees it as a tool that they themselves can use to build a pipeline of resuscitated drug candidates. The company plans to license their drug rescue variants to pharmaceutical companies pursuant to development and marketing arrangements designed to generate optimum revenue. They are also exploring opportunities to advance nonclinical development of potential cell therapy and regenerative medicine pilot programs focused on blood, cartilage, heart, liver, and pancreas cells, based on the proprietary differentiation and production capabilities of their stem cell technology platform.

    For additional information, visit VistaGen.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: VSTA
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.